Dr Bill Cham
HUMBLE, BUT REMARKABLE CONTRIBUTIONS TO SCIENCE FOR HUMANITY
CARDIOVASCULAR DISEASE (CVD)
Heart disease kills more people than any other disease. CVD kills 17.9 million people around the world every year – representing 32% of all global deaths.
Contributions towards treatment of CVD.
PUBLICATIONS
2015
Cham, B.E. (Not all “bad” cholesterol carriers are necessarily bad and not all “good” cholesterol carriers are as good as can be: plasma delipidation, a non-pharmacological treatment for atherosclerosis. Int. J. Clin. Med. 6(9), 690-699. DOI: 10.4236/ijcm.2015.69092
2013
Cham, B.E. and Chase, T.R. Intravascular infusion of autologous delipidated plasma induces antiatherogenic lipoproteins and causes regression of atherosclerosis. Studies in non-primates, monkeys and humans. Special Issue – Atherosclerosis in Cardiovascular Disease. Health 5, No.7A1, 19-33.
2007
Cham, B.E. Manipulation of reverse cholesterol transport system – An exploration for rapid regression of atherosclerosis. Res. J. Biol. Sci. 2(3), 291-300.
2005
Cham, B.E., Kostner, K.M., Shafey, T.M., Smith, J.L. and Colquhoun, D.M.
Plasma delipidation process induces rapid regression of atherosclerosis
and mobilization of adipose tissue. J. Clin. Apher. 20, 143-153.
2001
Cham, B.E., (2001). Plaque cholesterol and calcium: the value of EBCT in
the detection of coronary atherosclerosis. Eur J Clin Invest. 31, 467-468.
1999
Cham, B.E., Smith, J.L. and Colquhoun, D.M. Interdependence of serum concentrations of vitamin K1, vitamin E, lipids, apolipoprotein A1, and
apolipoprotein B: importance in assessing vitamin status. Clin. Chim Acta
287, 45-57.
Cham, B.E., Smith, J.L. and Colquhoun, D.M. What happens to vitamin K1 in serum after bone fracture? Clin Chem. 45, 2261-2263.
1998
Cham, B.E., Smith, J.L. and Colquhoun, D.M. Correlations between cholesterol vitamin E vitamin and K1 in serum: paradoxical relationships to establish epidemiological risk factors for cardiovascular disease. Clin. Chem. 44,1753-1756.
1997
Kostner, K.M., Smith, J.L., Dwivedy, A.K., Shafey, T., Fang, N.X., Mahon, M.G., Iannuzzi, C.I., Colquhoun, D.M. and Cham, B.E. Lecithin: cholesterol acyltransferase activity in normocholesterolemic and hypercholesterolemic rooster: modulation by lipid apheresis. Eur. J. Clin. Invest. 27, 212-218.
1996
Cham, B.E., Kostner K.M., Dwivedy, A.K., Shafey, T.M., Fang, N.X., Mahon, M.G., Iannuzzi, C.I., Colquhoun, D.M. and Smith, J.L. Lipid Apheresis in An Animal Model Causes In Vivo Changes in Lipoprotein Electrophoretic Patterns. J. Clin. Apher. 11,61-70.
1995
Cham, B.E., Kostner, K.M., Dwivedy, A.K., Shafey, T.M., Fang, N.X., Mahon, M.G., Iannuzzi, C.I., Colquhoun, D.M. and Smith, J.L. Lipid Apheresis: An In Vivo Application of Plasma Delipidation with Organic Solvents Resulting in Acute Transient Reduction of Circulating Plasma Lipids in Animals. J. Clin. Apher. 1995; 10, 61-69.
1994
Cham, B.E., Kostner, K.M., Colquhoun, D.M., and Dwivedy, A.K. Lipid-apheresis: an in vivo application of delipidation but apolipoprotein retention in plasma of calves by a continuous extracorporeal procedure. Atherosclerosis. 109, (1-2), 158.
Cham, B.E., Kostner, K.M., Colquhoun, D.M., and Dwivedy, A.K. Lipid-apheresis: an in vivo application of delipidation but apolipoprotein retention in plasma of pigs by a continuous extracorporeal procedure. Atherosclerosis. 109, (1-2), 159.
Cham, B. E., Colquhoun, D.M, Kostner, K.M., Shafey, T., Fang, N.X., Dwivedy, A.K., Mahon, M.G., and Iannuzzi, C. Rapid regression of atherosclerosis by lipid-apheresis. Asian-Pacific Congress on Lipid Factor Control. Hong Kong.
Cham, B.E. and Smith J.L. Lipid apheresis in an animal model causes acute reduction in plasma lipid concentrations and mobilisation of lipid from liver and aorta. Pharmacology (Life Sci. Adv.). 1994; 13, 25-32.
1992
Kostner, K., Cham, B.E., Dwivedy, A. and Fang, N.X. Increase of APO A1 Concentration in Hypercholesteraemic Chickens after Treatment with a newly developed Extracorporeal Lipid Elimination. XI International. Symposium on Drugs Affecting Lipid Metabolism. 13-16 May 1992.
Cham, B.E., Kostner, K., Shafey, T., Fang, N.X. and Dwivedy, A. Rapid Regression of Atherosclerosis by Cholesterol Apheresis – a Newly Developed Technique. 59th Congress European Atherosclerosis Society, Nice, France. 17-21 May 1992.
Fang, N.X., Dwivedy, A., Kostner, K., Shafey, T., Mahan, M., Cham, B.E. In Vivo Rapid Mobilisation of Adipose Tissue by Lipid Apheresis – a Newly Developed Technique. 18th Australian Atherosclerosis Society. Conference, Gold Coast, Queensland, Australia.
Dwivedy, A., Kostner, K., Fang, N.X., Shafey, T., Cham, B.E. Increase of Reverse Cholesterol Transport by Cholesterol Apheresis: Regression of Atherosclerosis. 18th Australian Atherosclerosis Society Conference, Gold Coast, Queensland, Australia.
Mahon, M., Kostner, K., Fang, N.X., Shafey T., Cham, B.E. Rapid Regression of Atherosclerosis by Cholesterol Apheresis – a Newly Developed Technique. 18th Australian Atherosclerosis Society Conference, Gold Coast, Queensland, Australia.
1982
Cham, B.E., Roeser, H.P., Warrell, A., Linton, I., Owens, P. and Gaffney, T. Effect of high energy, low-carbohydrate diet on serum levels of lipids and lipoproteins. Internal Medicine Digest. October, p.8.
Cham, B.E. (1982). Studies on human serum lipoproteins. Ph.D. Thesis,
University of Queensland. 187 pp.
1981
Cham, B.E., Roeser, H.P., Warrell, A., Linton, I., Owens, P. and Gaffney, T. Effect of a high energy low carbohydrate diet on serum levels of lipids and lipoproteins. Med. J. Australia 1, 237-240.
Cham, B.E., Owens, P., Roeser, H.P., Gaffney, T. and Shanley, B.C. Heterogeneity of lipoprotein B. Biochem. Biophys. Res. Commun. 103, 196-206.
1978
Cham, B.E. (1977). The effect of phenformin and heparin on serum lipoproteins. Protides Biol. Fluids 25, 371-378.
Cham, B.E., Owens, P., Knowles, B.R., Gaffney, T. and Roeser, H.P. Heterogeneity of Lipoprotein B. Research in progress. National Heart Foundation of Australia, p.6.
Cham, B.E., Owens, P., Knowles, B.R., Gaffney, T. and Roeser, H.P. Heterogeneity of Lipoprotein B. Research in progress. National Heart Foundation of Australia, p.6.
Linton, I., Warrel, A., Cham, B.E. and Owens, P. Diet-induced alterations of serum lipids and lipoproteins. Clin. Exp. Pharmacol. 6(4), 446.
1977
Cham, B.E. (1977). In vitro interactions of phenformin with serum lipoproteins (Abstract No. 82). Clin. Exp. Ph. 4, 509.
Cham, B.E. (1977). In vitro interactions of phenformin with serum lipoproteins and consequences thereof. Chem-Biol. Interact. 17, 193-201.
1976
Cham, B.E. and Knowles, B.R. (Relipidation of apolipoproteins in plasma. (Abstract No. 39) Clin. Exp. Pharmacol. 3, 257.
Cham, B.E. and Knowles, B.R. A solvent system for delipidation of plasma or serum without protein precipitation. J. Lipid Res. 17, 176-181.
Cham, B.E. and Knowles, B.R. Changes in electrophoretic mobilities of alpha and beta lipoproteins as a result of plasma delipidation. Clin. Chem. 22, 305-309.
Cham, B.E. and Knowles, B.R. In vitro partial relipidation of apolipoproteins in plasma. J. Biol. Chem. 251, 6367-6371.
Cham, B.E. Nature of the interaction between low density lipoprotein and polyanions and metal ions as exemplified by heparin and Ca++. Clin. Chem. 22, 1812-1816.
1975
Cham, B.E., Johnson, G.W. and Knowles, B.R. Delipidation of plasma lipoproteins (Abstract No. 67). Clin. Exp. Pharmacol. 2,74.
Cham, B.E. and Knowles, B.R. In-vitro observations of the effect of phenformin on serum lipids. Artery. 1, 334-335.
1973
Cham, B.E., Hurwood, J.J., Knowles, B.R. and Powell, L.W. Rapid, sensitive method for the separation of free cholesterol from ester cholesterol. Clinica Chimica Acta. 49, 109-113.
PATENTS
Patent Family 4: Delipidation – Treatment for cardiovascular and related
diseases
Patent Family 5: Delipidation – Treating Alzheimers using delipidated protein
particles
INVENTIONS
Treatment of atherosclerosis by cholesterol apheresis.
A plasma delipidation system.
Treatment of cardiovascular and related diseases.
Solvent extraction methods for delipidating plasma.
Autologous plasma delipidation using a continuous flow system.
CANCER (ONCOLOGY)
Cancer is a leading cause of death worldwide, accounting for 10 million deaths in 2020. Skin cancer …..
Contributions towards treatments of Cancer.
PUBLICATIONS
2025
K.E. Cham, T.R. Chase, and B.E. Cham. Enhanced Analysis and Simplification of Scientific Findings with Emphasis on Katabasis and Anabasis on Safe and Effective Skin Cancer Treatment Using Curaderm. Journal of Cancer Therapy. 16(4), 125-137. Doi: 10.4236/jct.2025.164011
2024
T.R. Chase, K.E. Cham and B.E. Cham. Unique Clinical Features of Curaderm when Treating Skin Cancers. Journal of Cancer Therapy. 15, 13-27.
Doi: 10.4236/jct.2024.151002
T.R. Chase, K.E. Cham and Cham, B.E. (2024). The Value of Excipients and the Required Understanding of the Biological System in Product Development: An Impactful Example of Curaderm, a Topical Skin Cancer Treatment. International Journal of Clinical Medicine. 15, 68-87. Doi: 10.4236/ijcm.2024.152005
Cham, B.E. Gold Standard for Skin Cancer Treatment: Surgery (Mohs) or Microscopic Molecular-Cellular Therapy (Curaderm)? Journal of Cancer Therapy. 15, 33-47. Doi: 10.4236/jct.2024.152004
2023
Cham, B.E. Holistic Approach in the Treatment of Actinic Keratosis: Benefits and Disadvantages of 5-Fluorouracil, Imiquimod, Diclofenac and Curaderm. International Journal of Clinical Medicine. 14,319-331.
Doi: 10.4236/ijcm.2023.147027
2022
Cham, B.E. The Pharmacology of Curaderm in the Treatment of Basal Cell Carcinoma. Clinical Medicine Review and Case Reports. 9, 399.
Doi: 10.23937/2378-3656/1410399
2021
The Evolution of Curaderm which led to the Revolution of Skin Cancer treatment. eBook. Cham, B.E. Amazon US. https://www.amazon.com/EVOLUTION-CURADERM-EGGPLANT-REVOLUTION-TREATMENT-ebook/dp/B09MVP5M3L/ref=sr_1_1?keywords=the+evolution+of+curaderm&qid=1639040738&sr=8-1
2020
Cham, B.E. First in Man Topical Treatment of Melanoma with Solasodine Glycosides in a Formulation Curaderm. Journal of Cancer Therapy. 11(10), 617-630. Doi: 10.4236/jct.2020.1110052
Cham, B.E. Critical study on topical CuradermBEC therapy for periocular nonmelanoma skin cancers: A review of clinical outcomes. Current topics in Med. Medical Research. ISBN: 978-93-90149-59-9. Vol 1, 142-151.
Doi: 10.4236/ijcm.2013.45041
Cham, B.E. Combination Treatment with BEC and Cisplatin Synergistically Augments Anticancer Activity and Results in Increased Absolute survival. Journal of Cancer Therapy. 11(8), 470-482. Doi: 10.4236/jct.2020.118040
Chase, T., Cham, K.E., Cham, B.E. Evaluation of Dermal Irritation and Skin Sensitization by Curaderm. International Journal of Clinical Medicine. 11(9), 548-558. Doi: 10.4236/ijcm.2020.119047
Chase, T., Cham, K.E. Cham, B.E. Curaderm, the Long-Awaited Breakthrough for Basal Cell Carcinoma. International Journal of Clinical Medicine. 11(10), 579-604.
Doi: 10.4236/ijcm.2020.1110050
2019
Cham, B.E. Solasodine glycosides from the eggplant in a topical cream PsorendBEC are effective against Psoriasis. International Journal Clinical Medicine. 10(3), 174-182. Doi: 10.4236/ijcm.2019.103017
2017
Cham, B.E. Solasodine, solamargine and mixtures of solasodine rhamnosides: Pathway to expansive clinical anticancer therapies. International Journal of Clinical Medicine. 8(12), 692-713. Doi: 10.4236/ijcm.2017.812064
2016
Batsev, A.F., Dobrokhotova, V.Z. and Cham, B.E. Topical cream CuradermBEC5 Treats a Recalcitrant Basal Cell Carcinoma. Clinical Medicine Reviews and Case Reports. 3:098, 3(3) 1-3. Doi: 10.23937/2378-3656/1410098
Tambuscio, A., Siliprandi, L., Dario, M., Cham, A., Cham, B. E. and Bordignon, M. Treatment of cutaneous carcinomas with a topical cream containing solasodine rhamnosides: Focus on efficacy, compliance and cosmetic outcomes. European Academy of Dermatology and Venereology Congress. Athens, Greece.
Cham, B.E. Plant extracted solasodine rhamnosides, a new era for cancer therapy? International Conference on Cancer Research & Targeted Therapy. October 21-23. Baltimore, MD, USA (CRT-2016).
Cham, B. E. Plant derived glycoalkaloids in cancer treatment, from the lab to the clinic. The Truth About Cancer. Ultimate Live Symposium, 36-40. October 14-16, Grapevine, Texas, USA.
2015
Cham, A., Cham, K., Chase T. and Cham, B.E. A standardized plant extract containing a target compound is acceptable as a potent therapeutic entity: relevance to BEC and solamargine, a topical clinical formulation CuradermBEC5. Journal Cancer Treatment and Research. 3(2), 22-27.
Doi: 10.11648/j.jctr.20150302.12
Cham, A and Cham, B.E. Treatment of skin cancer with a selective apoptotic–inducing CuradermBEC5 topical cream containing solasodine rhamnosides. International Journal Clinical Medicine. 6(5), 326-333.
Doi: 10.4236/ijcm.2015.65042
Cham, B.E. CuradermBEC5, Natural Non-Invasive Medication * For Skin Cancer. *Biopsy and 5-year cancer-free criteria. 2nd Edition Curaderm Global Ltd. ISBN-13: 978-0-646-92463-2.
Cham, B.E., Cham, K., Cham, A., Chase, T. and Zhou, V. Treatment of non-melanoma skin cancers: An intra-Comparison study of CuradermBEC5 and various established modalities. Journal Cancer Therapy. 6(12), 1045-1053.
Doi: 10.4236/jct.2015.612114
2014
Cham, B.E. A Review of Solasodine Rhamnosides Therapy for in-situ squamous cell carcinoma on the Penis. Journal of Advances in Medicine and Medical Research. 4(2), 621-631. Doi: 10.9734/BJMMR/2014/4677
CuradermBEC5, Natural Non-Invasive Cure * For Skin Cancer. *Biopsy and 5-year cancer-free criteria. 1st Edition Curaderm Global Ltd. Cham, B.E. ISBN-13: 978-0-646-92463-2.
2013
Cham, B.E. Inspired by Nature, Proven by Science. The new generation cancer treatment that causes cancer cells to commit suicide. ISBN=978-1-62951-158-0.
Cham, B.E. Topical Curaderm BEC5 Therapy for Periocular Nonmelanoma Skin Cancer: A Review of Clinical Outcomes. International Journal of Clinical Medicine. 4(5), 233-238. Doi: 10.4236/ijcm.2013.45041
Cham, B.E. Solasodine Glycosides: A Topical Therapy for Actinic Keratosis. A Single-Blind, Randomized, Placebo-Controlled, Parallel Group Study with CuradermBEC5. Journal of Cancer Therapy. 4(2), 588-596.
Doi: 10.4236/jct.2013.42076
Cham, B.E. Drug Therapy: Solamargine and other solasodine rhamnosyl glycosides as anticancer agents. Modern Chemotherapy. 2(2), 33-49.
Doi: 10.4236/mc.2013.22005
2012
Cham, B.E. and Chase T.R. Solasodine Rhamnosyl Glycosides Cause Apoptosis in Cancer Cells, Do They Also Prime the Immune System Resulting in Long Term Protection? Planta Medica. 78(4), 349-353. Doi: 10.1055/s-0031-1298149
Cham, B.E. Intralesion and Curaderm BEC topical Combination Therapies of Solasodine Rhamnosyl Glycosides Derived from the Eggplant or Devil’s Apple Result in Rapid Removal of Large Skin Cancers. Methods of Treatment Compared. International Journal of Clinical Medicine. 3(2), 115-124.
Doi: 10.4236/ijcm.2012.32024
2011
Cham, B.E. Topical Solasodine Rhamnosyl Glycosides Derived from the Eggplant Treats Large Skin Cancers: Two Case Reports. International Journal of Clinical Medicine. 2(4), 473-477. Doi: 10.4236/ijcm.2011.24080
Chase T. R. Curaderm BEC5 For Skin Cancers, Is It? An Overview. Journal Cancer Therapy. 2, 728-745. Doi: 10.4236/jct.2011.25099
2009
Cham, B.E. When does alternative become orthodox? Skin cancer treatment with solasodine rhamnosyl glycosides in its transitional stage, a case study. Evidence-Based Complementary and Alternative Medicine. 6(3), 415-420.
2008
Cham, B.E. Cancer intralesion chemotherapy with solasodine rhamnosyl glycosides. Research Journal of Biological Sciences. 3(9), 1008-1017.
2007
Cham, B.E. The Eggplant Cancer Cure: A Treatment for Skin Cancers and New Hope for Other Cancers from Nature’s Pharmacy. Smart Publications.
Cham, B.E. Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and Necrosis. Treatment for Skin Cancer and Hope for Internal Cancers. Research Journal of Biological Sciences. 2(4), 503-514.
Cham, B.E. Solasodine rhamnosyl glycosides in a cream formulation is effective for treating large and troublesome skin cancers. Research Journal of Biological Sciences. 2(7), 749-761.
Cham, B.E. Advances in the Eradication of Skin Cancer. Proceedings ICIM Conference – Kentucky USA.
2006
Cham, B.E. The discovery of a natural cream that eats cancer. International Antiaging. 37-39.
2005
Cham, B.E. BEC5-Curaderm, the treatment of choice for non-melanoma skin cancers. International Antiaging. 7-10.
1998
Cham, B.E. Specificity of solasodine glycosides towards cancer cells, pre-clinical and clinical observations. Proc. 3rd World Congress on Cancer. Indep. Med. Research.
1995
Cham, B.E. Solasodine glycosides as anti-cancer agents: Pre-clinical and clinical studies. Proc. 2nd World Congress on Cancer. Indep. Med. Res. 1996; 111-114.
1994
Cham, B.E. Solasodine glycosides as anti-cancer agents: Pre-clinical and clinical studies. Asia Pacific Journal of Pharmacology. 9, 113-118.
1993
Cham, B.E. Efficacy and mode of action of solasodine glycosides (BEC) on cancer cells. In Proc. 4th Oceania
1992
Cham, B.E., Daunter, B. and Evans, R. Topical treatment of malignant and premalignant skin cancers by very low concentrations of A standard mixture of solasodine glycosides. Clinical Digest Series. Dermatology. 1992.
1991
Cham, B.E., Daunter, B. and Evans, R. Topical treatment of malignant and premalignant skin cancers by very low concentrations of a standard mixture (BEC) of solasodine glycosides. Cancer Letters. 59, 183-192.
Doi: 10.1016/0304-3835(91)90140-D
Cham, B.E. Solasodine glycosides; A new modality for cancer. In Proc. 2nd Oceania Symposium. Pp. 30-36. Editor Mark S. Walker. BoConcepts Publishing.
1990
Cham, B.E., Daunter, B. and Evans, R. Topical treatment for pre-malignant and malignant skin cancers with Curaderm. Drugs of Today. 26, 55-58.
Cham, B.E. and Daunter, B. Curaderm. Medical Journal of Australia. 152, 329-330.
Daunter, B. and Cham, B.E. Solasodine glycosides. In vitro preferential cytotoxicity for human cancer cells. Cancer Letters. 55, 209-220.
Doi: 10.1016/0304-3835(90)90121-D
Cham, B.E. and Daunter, B. Solasodine glycosides. Selective cytoxicity for cancer cells and inhibition of cytotoxicity by rhamnose in mice with sarcoma 180. Cancer Letters. 55, 221-225. Doi: 10.1016/0304-3835(90)90122-e
1989
Cham, B.E. Curaderm (antineoplastic). Launched in Australia. Drug News and Perspectives. 2, 112.
Cham, B.E. Plants yield skin cancer cure. Australian Technology Review. 2, 53.
Evans, R., Cham, B.E. and Daunter, B. Letter to the Editor. Medical Journal of Australia. 150, 350-351.
Evans, R., Cham, B.E. and Daunter, B. Letters to the Editor. Your Pharmacy, January 1.
1988
Cham, B.E. Monograph on the compound BEC. Drugs of the Future. 13, 714-716.
1987
Cham, B.E. and Wilson, L. HPLC of glycoalkaloids from Solanum sodomaeum L. Planta Medica. 53, 59-62. Doi: 10.1055/s-2006-962621
Cham, B.E., Gilliver, M. and Wilson, L. Antitumour effects of glycoalkaloids isolated from Solanum sodomaeum L. Planta Medica. 53, 63-64.
Doi: 10.1055/s-2006-962612
Cham, B.E. and Meares, H.M. Glycoalkaloids from Solanum sodomaeum L. are effective in the treatment of skin cancers in man. Cancer Letters 36. 111-118.
Doi: 10.1016/0304-3835(87)90081-4
PATENTS
Patent Family 1: Glycoalkaloids
Patent Family 2: Medicinal Compositions and their Method of Preparation
Patent Family 3: Glycoalkaloid Combinations and Various Uses Thereof
INVENTIONS
Glycoalkaloids
Treatment of sunspots, keratoses, basal cell carcinoma and squamous cell carcinoma (skin cancers).
Therapeutic compositions and their method of preparation.
VIRAL DISEASES
Recent emergence of diseases like HIV/AIDS, Sars, COVID-19 are unpredicted major killers worldwide.
Contributions towards vaccine development.
PUBLICATIONS
2021
Cham, B.E. Defatting Covid-19 Virus Exposes Hidden Proteins Allowing Robust Vaccines that also Resist Infection of Mutated Strains. Yorkpedia. 3rd May 2021.
Cham, B.E. New and Newer Vaccines for SARS-CoV-2 Variants. Are the Major Vaccine Developers on the Right Track, Or Is Delipidation the Answer? Journal Advances in Infectious Diseases. 11(2), 165-170. Doi: 10.4236/aid.2021.112016
2007
Cham, B.E. Manipulation of reverse cholesterol transport system – an exploration for rapid regression of atherosclerosis. Research Journal Biological Sciences. 2(3), 291-300.
Cham, B.E. Delipidation of a pestivirus: viral inactivation and. vaccine development in large animals. Research Journal Biological Sciences. (7), 706-712.
PATENTS
Patent Family 6: Delipidation – Vaccine
INVENTIONS
A method of treating infectious diseases.
A vaccine.
Method of treating infectious diseases.
Method of treating and preventing infectious diseases.
Method of making modified immunodeficiency virus particles.
Modified viral particles with immunogenic properties and reduced lipid content.
Modified immunodeficiency virus particles.
Method of treating and preventing infectious diseases.
OTHER METABOLIC DISEASES
Metabolic disorders negatively alter the body’s processing and distribution of macronutrients and are significant contributes to global mortality.
Contributions towards improving metabolic diseases.
PUBLICATIONS
1991
Booth, C.B., Cannell, G.R., Roeser, H.P. and Cham, B.E. Disposition of vitamin K1 (phylloquinone) in isolated perfused human placenta. Nutrition Research. 11, 283-293.
1990
Cham, B.E., Roeser, H.P. and Nikles, A. Ascorbic acid deficiency affects the metabolism of cytosolic ferritin but not lipid-associated ferritin in livers of guinea pigs. Biochem. J. 267, 535-537.
1989
Cham, B.E., Roeser, H.P. and Nikles, A. Cytosolic ferritin and lipid-associated ferritin are metabolically different in guinea pig livers. Biochem. J. 263, 989-992.
Cham, B.E., Roeser, H.P. and Kamst, J. Liquid-chromatographic method for the simultaneous determination of vitamin K1 and vitamin E in serum. Clin. Chem. 35, 2285-2289.
1988
Cham, B.E., Roeser, H.P. and Nikles, A. Effects of non-ionic and anionic detergents on lipid-associated tissue ferritin. Clin. Chem. 34, 152-155.
1986
Roeser, H.P., Cham, B.E., Nikles, A. and Ridgway, K. Vitamin E supplements modify the response of guinea pigs to a scorbutogenic diet. Vitaminologia 2, 101-108.
Cham, B.E., Roeser, H.P., Nikles, A. and Ridgway, K. Lipid-associated tissue ferritin. Clin. Chim. Acta 158, 71-79.
Cham, B.E. Aspirin, platelets and thrombosis. Prospects for Prophylaxis – Low Dose Aspirin in Cardiovascular Disease. (Ed. By B Cham). Adis Press, Auckland, New Zealand.
1985
Cham, B.E., Roeser, H.P., Nikles, A. and Ridgway, K. A procedure for the purification of ferritin from human liver. Anal. Biochem. 151, 561-565.
1984
Gunsberg, H., Bochner, F., Graham, G., Imhoff, D., Parsons, G. and Cham, B.E. The disposition of and clinical response to salicylates in patients with rheumatoid disease. Clinical Pharmacology. Ther. 35, 585-593.
1983
Roeser, H.P., Sizemore, D.J., Nikles, A. and Cham, B.E. Tissue ferritin in scorbutic guinea pigs. British Journal Haematology. 55, 325-333.
1982
Roeser, H.P., Nikkles, A. and Cham, B.E. Effects of ascorbic acid deficiency on ferritin turnover. The Biochemistry and Physiology of Iron (ed. By P. Saltman and J. Hegenauer), p. 385-393. Elsevier Biomedical, New York.
Cham, B.E., Bochner, F., Imhoff, D., Byrne, G., and Gunsberg, M. In vivo and in vitro studies on the binding of salicylate to human plasma proteins. Evidence for one type of binding site. Journal Pharmacology. Exp. Ther. 220, 648-653.
Ross-Lee, L.M., Elms, M.J., Cham, B.E., Bochner, F., Bunce, I.H. and Eadie, M.J. (1982). Plasma levels of aspirin following effervescent and enteric coated tablets, and their effect on platelet function. European Journal Clinical Pharmacology. 23, 545-551.
Cham, B.E., Dykman, J. and Bochner, F. (1982). Urinary excretion of aspirin. Br. Journal Clinical Pharmacology. 14, 562-574.
1981
Bochner, F., Graham, G.G., Cham, B.E. and Imhoff, D.M. Salicylate metabolite kinetics after several salicylates. Clinical Pharmacology. Ther, 30, 266-275.
McCafferty, J., Brophy, T, R.O.R., Yelland, J.D., Cham, B.E., Bochner, R and Eadie, M.J. Intraoperative pharmacokinetics of dexamethasone. Journal Clinical Pharmacology. 12, 434-436.
1980
Axelsen, R.A., Bochner, F., Cartwright, V.E., Imhoff, D.C. and Cham, B.E. Analgesic-induced renal papillary necrosis and salicylate metabolism in the Gunn rat. Australia N.Z Journal Medicine. 10, 130.
Gunsberg, M., Cham, B.E., Imhoff, D.M., Parsons, G., Bochner, F. and Johnson, F.L. Correlation of aspirin dose with concentrations of salicylic acid in plasma, plasma water and saliva and clinical response in patients with rheumatoid disease. Aust. N.Z. Journal Medicine. 10, 268-269.
Cham, B.E., Bochner, F., Gunsberg, M., Imhoff, D.M. and Byrne, G.J. In vivo plasma protein binding of salicylic acid in humans. Clinical Pharmacology. Ther Abstract 0175.
Bochner, F., Cham, B.E., Graham, G.G., Imhoff, D.M. Pharmacokinetics of salicylates in humans. Clinical Pharmacology. Ther. Abstract 0174.
Cham, B.E., Bochner, F., Imhoff, D.M. and Rowland, M. Simultaneous liquid chromatographic quantitation of salicylic acid, salicyluric acid, and gentisic acid in urine. Clin. Chem. 26, 11-114.
Cham, B.E., Sadowski, B., O’Hagen, J.M., de Wytt, C.N., Bochner, F. and Eadie, M.J. High performance liquid chromatographic assay of dexamethasone in plasma and tissue. Ther. Drug. Monit. 2, 373-377.
Cham, B.E., Ross-Lee, L., Bochner, F. and Imhoff, D.M. Measurement and pharmacokinetics of acetylsalicylic acid by a novel high performance liquid chromatographic assay. Ther. Drug. Monit. 2, 365-372.
1979
Cham, B.E., Johns, D., Bocher, F., Imhoff, D.M. and Rowland, M. Simultaneous liquid-chromatographic quantitation of salicylic acid, salicyluric acid and gentisic acid in plasma. Clin. Chem. 25, 1420-1425.
Bochner, F., Cham, B.E., Graham, G.G. and Imhoff, D.M. Pharmacokinetics of salicylurate in humans following single oral dose of aspirin and sodium salicylate. Proc. Austral. Physiol and Pharmacology. Society 10,265P.
Eadie, M.J., Cotter, L.M., Kratzing, L., Cham, B.E. and Tyrer, J.H. Aspirin in migraine treatment. Proc. Austral Physiol and Pharmacology. Society 10, 107P.
Imhoff, D.M., Cham, B.E., Cotter, L.M. and Bochner, F. Pharmacokinetics of aspirin in healthy human volunteers using a novel high performance liquid chromatographic assay. Proc. Austral. Physiol and Pharmacology. Society 10, 327P.
1973
Bochner, F., Cham, B.E., Eadie, M.J., Hooper, W.D., Knowles, B.R., Sutherland, J.M. and Tyrer, J.H. Possible acute liver toxicity from the hypolipidemic agent 1-methyl-4-piperidylbis (p-chlorophenoxy)-acetate. Tox. Applied Pharmacology. 24, 653-656.
1972
French, T.J., Cham, B.E. and Cross, R.B. Routine method for the estimation of ionic calcium activity and concentration in biological solutions. Lab. Practice. 21, 333-339.
Cham, B.E. A semiautomated method for the estimation of ionic calcium activity and concentration in biological solutions. Clin. Chim. Acta. 37, 5-14.
1971
French, T.J., Cham, B.E. and Cross, R.B. Modified synthesis of tetramethylmurexide. Lab. Practice. 20,424.